To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual insiders with 81% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, insiders scored the highest last week as the company hit US$397m market cap following a 15% gain in the stock.
Let's delve deeper into each type of owner of Regencell Bioscience Holdings, beginning with the chart below.
Check out our latest analysis for Regencell Bioscience Holdings
NasdaqCM:RGC Ownership Breakdown November 16th 2022
What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors.
There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. Alternatively, there might be something about the company that has kept institutional investors away. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Regencell Bioscience Holdings, for yourself, below.
NasdaqCM:RGC Earnings and Revenue Growth November 16th 2022
Regencell Bioscience Holdings is not owned by hedge funds. The company's CEO Yat-Gai Au is the largest shareholder with 81% of shares outstanding. With such a huge stake, we infer that they have significant control of the future of the company. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider with such skin in the game. Meanwhile, the second and third largest shareholders, hold 7.6% and 0.05%, of the shares outstanding, respectively.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems that insiders own more than half the Regencell Bioscience Holdings Limited stock. This gives them a lot of power. So they have a US$322m stake in this US$397m business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
Private equity firms hold a 7.6% stake in Regencell Bioscience Holdings. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Regencell Bioscience Holdings (of which 1 is a bit unpleasant!) you should know about.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
要弄清楚谁真正控制了脑再生科技控股有限公司(纳斯达克代码:RGC),了解该公司的所有权结构是很重要的。而持有这块蛋糕最大份额的是个人内部人士,拥有81%的股份。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
因此,内部人士上周的得分最高,该公司在股价上涨15%后,市值达到3.97亿美元。
让我们从下面的图表开始,更深入地研究脑再生科技控股的每一种类型的所有者。
查看我们对脑再生科技控股的最新分析
NasdaqCM:RGC所有权明细2022年11月16日
机构所有的缺失告诉了我们关于脑再生科技控股的什么信息?
机构投资者往往会避开那些规模太小、流动性太差或风险太高的公司,这些公司对他们的口味来说太小了。但在没有任何机构投资者的情况下,看到较大的公司并不常见。
一家公司可能没有在股票登记处登记任何机构的原因有很多。如果流动性(每天交易的股票数量)很低,机构可能很难购买大量股票。如果该公司不需要筹集资金,机构可能缺乏建立头寸的机会。或者,该公司可能有某些方面让机构投资者望而却步。机构投资者可能不会觉得这项业务的历史性增长令人印象深刻,或者可能有其他因素在起作用。你可以在下面看到脑再生科技控股过去的收入表现,为你自己。
纳斯达克CM:RGC收益和收入增长2022年11月16日
脑再生科技控股并非为对冲基金所有。该公司首席执行官欧逸杰是最大股东,持有81%的流通股。拥有如此庞大的股份,我们推断他们对公司的未来有很大的控制权。当内部人持有公司大量股份时,这通常被认为是一个好兆头,在这种情况下,我们很高兴看到公司内部人士有这样的皮肤。与此同时,第二大和第三大股东分别持有7.6%和0.05%的流通股。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。据我们所知,没有分析师对该公司的报道,所以它很可能在雷达下飞行。
脑再生科技控股的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
看来,内部人士持有脑再生科技控股有限公司一半以上的股份。这给了他们很大的权力。因此,他们在这项价值3.97亿美元的业务中持有3.22亿美元的股份。大多数人会辩称,这是积极的,表明了与股东的强烈一致。你可以点击这里,看看这些内部人士是一直在买入还是卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司11%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私募股权所有权
私募股权公司持有脑再生科技控股7.6%的股份。这表明,他们可以在关键的政策决策中发挥影响力。一些人可能会喜欢这样,因为私人股本有时是让管理层承担责任的积极分子。但在其他时候,私募股权公司让公司上市后,它们的股票都卖光了。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。比如风险。每家公司都有它们,我们已经发现脑再生科技控股的2个警告信号(其中1个有点不愉快!)你应该知道。
当然了这可能不是最值得购买的股票。。因此,您可能希望看到我们的免费一组有趣的潜在客户,拥有有利的财务状况。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。